- Home
- TCRX vs MOLN Comparison
TCRX vs MOLN Comparison
Compare TCRX & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCRX
- MOLN
- Stock Information
- Founded
- TCRX 2018
- MOLN 2004
- Country
- TCRX United States
- MOLN Switzerland
- Employees
- TCRX N/A
- MOLN N/A
- Industry
- TCRX Biotechnology: Pharmaceutical Preparations
- MOLN
- Sector
- TCRX Health Care
- MOLN
- Exchange
- TCRX Nasdaq
- MOLN Nasdaq
- Market Cap
- TCRX 140.7M
- MOLN 142.5M
- IPO Year
- TCRX 2021
- MOLN 2021
- Fundamental
- Price
- TCRX $1.92
- MOLN $3.75
- Analyst Decision
- TCRX Strong Buy
- MOLN Hold
- Analyst Count
- TCRX 5
- MOLN 1
- Target Price
- TCRX $9.40
- MOLN $4.00
- AVG Volume (30 Days)
- TCRX 648.1K
- MOLN 2.0K
- Earning Date
- TCRX 11-07-2025
- MOLN 03-12-2026
- Dividend Yield
- TCRX N/A
- MOLN N/A
- EPS Growth
- TCRX N/A
- MOLN N/A
- EPS
- TCRX N/A
- MOLN N/A
- Revenue
- TCRX $6,961,000.00
- MOLN $856,302.00
- Revenue This Year
- TCRX $255.18
- MOLN N/A
- Revenue Next Year
- TCRX N/A
- MOLN $1,000.00
- P/E Ratio
- TCRX N/A
- MOLN N/A
- Revenue Growth
- TCRX N/A
- MOLN N/A
- 52 Week Low
- TCRX $1.02
- MOLN $3.36
- 52 Week High
- TCRX $6.23
- MOLN $6.63
- Technical
- Relative Strength Index (RSI)
- TCRX 41.52
- MOLN 51.45
- Support Level
- TCRX $2.23
- MOLN $3.53
- Resistance Level
- TCRX $2.43
- MOLN $3.92
- Average True Range (ATR)
- TCRX 0.19
- MOLN 0.09
- MACD
- TCRX -0.04
- MOLN -0.01
- Stochastic Oscillator
- TCRX 1.52
- MOLN 46.81
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.